{"id":"lapatinib-gw572016","safety":{"commonSideEffects":[{"rate":"60","effect":"Diarrhea"},{"rate":"50","effect":"Hand-foot skin reaction"},{"rate":"40","effect":"Nausea"},{"rate":"35","effect":"Fatigue"},{"rate":"30","effect":"Rash"},{"rate":"25","effect":"Vomiting"},{"rate":"20","effect":"Dyspepsia"},{"rate":"5","effect":"Left ventricular dysfunction"}]},"_chembl":{"chemblId":"CHEMBL554","moleculeType":"Small molecule","molecularWeight":"581.07"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Lapatinib reversibly inhibits the intracellular tyrosine kinases of human epidermal growth factor receptors HER2 and EGFR. By blocking these kinases, it prevents downstream signaling pathways that drive proliferation in HER2-positive and EGFR-dependent cancers. This dual inhibition makes it particularly effective in breast cancers that overexpress HER2.","oneSentence":"Lapatinib is a small-molecule tyrosine kinase inhibitor that blocks HER2 and EGFR signaling to inhibit cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:20.192Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer (in combination with capecitabine)"},{"name":"HER2-positive early-stage breast cancer (adjuvant therapy)"}]},"trialDetails":[{"nctId":"NCT01612351","phase":"PHASE2","title":"Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2012-06","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":40},{"nctId":"NCT03523585","phase":"PHASE3","title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-08-01","conditions":"Breast Cancer","enrollment":608},{"nctId":"NCT07416409","phase":"","title":"Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Deraya University","startDate":"2023-06-10","conditions":"Breast Neoplasms, Oncology, HER2-positive Breast Cancer","enrollment":80},{"nctId":"NCT06828588","phase":"EARLY_PHASE1","title":"Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-02","conditions":"Locally Advanced Cancer, Metastatic Cancer, HER2","enrollment":30},{"nctId":"NCT01494662","phase":"PHASE2","title":"HKI-272 for HER2-Positive Breast Cancer and Brain Metastases","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-02","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT02158507","phase":"NA","title":"Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-09-04","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT03784014","phase":"PHASE3","title":"Molecular Profiling of Advanced Soft-tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-10-19","conditions":"Soft Tissue Sarcoma","enrollment":603},{"nctId":"NCT01771458","phase":"PHASE2","title":"A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2012-10","conditions":"Reccurent/Metastatic Solid Tumor Disease","enrollment":742},{"nctId":"NCT01947023","phase":"PHASE1","title":"Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-09-27","conditions":"Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma","enrollment":21},{"nctId":"NCT01382706","phase":"PHASE2","title":"Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2011-06-13","conditions":"Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer","enrollment":15},{"nctId":"NCT07152782","phase":"PHASE2","title":"T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11","conditions":"Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer","enrollment":202},{"nctId":"NCT00770809","phase":"PHASE3","title":"Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-02-24","conditions":"Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7","enrollment":305},{"nctId":"NCT02029001","phase":"PHASE2","title":"Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2014-03","conditions":"Malignant Solid Neoplasms","enrollment":900},{"nctId":"NCT00680901","phase":"PHASE3","title":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06-04","conditions":"Neoplasms, Gastrointestinal Tract","enrollment":545},{"nctId":"NCT04135807","phase":"EARLY_PHASE1","title":"Implantable Microdevice In Primary Brain Tumors","status":"RECRUITING","sponsor":"Oliver Jonas","startDate":"2020-03-03","conditions":"Grade II Glioma, Grade III Glioma, Grade IV Glioma","enrollment":12},{"nctId":"NCT02230553","phase":"PHASE1, PHASE2","title":"Lapatinib Plus Trametinib in KRAS Mutant NSCLC","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2014-10-07","conditions":"Colorectal Cancer","enrollment":35},{"nctId":"NCT04608409","phase":"PHASE1","title":"Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer","status":"COMPLETED","sponsor":"Frederick R. Ueland, M.D.","startDate":"2021-03-17","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT01273610","phase":"PHASE2","title":"Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2011-04-20","conditions":"Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services","enrollment":40},{"nctId":"NCT01526369","phase":"PHASE3","title":"A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2012-02-13","conditions":"Metastatic Breast Cancer","enrollment":75},{"nctId":"NCT06313983","phase":"PHASE3","title":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer","status":"RECRUITING","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2022-01-08","conditions":"Breast Cancer","enrollment":339},{"nctId":"NCT00490139","phase":"PHASE3","title":"ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-05-16","conditions":"Neoplasms, Breast","enrollment":8381},{"nctId":"NCT00667251","phase":"PHASE3","title":"Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10-07","conditions":"Breast Cancer","enrollment":652},{"nctId":"NCT00999804","phase":"PHASE2","title":"Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor Breast Care Center","startDate":"2011-10","conditions":"Breast Cancer","enrollment":128},{"nctId":"NCT01160211","phase":"PHASE3","title":"A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05-05","conditions":"Neoplasms, Breast","enrollment":369},{"nctId":"NCT00881621","phase":"PHASE2","title":"Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2009-08","conditions":"Pancreas Cancer","enrollment":17},{"nctId":"NCT00470704","phase":"PHASE2","title":"Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Nancy Lin, MD","startDate":"2007-05-14","conditions":"Breast Cancer","enrollment":87},{"nctId":"NCT02101905","phase":"PHASE1","title":"Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-11-07","conditions":"Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma","enrollment":29},{"nctId":"NCT01306045","phase":"PHASE2","title":"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-08","conditions":"Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic","enrollment":647},{"nctId":"NCT00963547","phase":"PHASE1","title":"A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-15","conditions":"Advanced Solid Tumors, Breast Cancer","enrollment":33},{"nctId":"NCT01619111","phase":"PHASE3","title":"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs","status":"COMPLETED","sponsor":"Prof. Wolfgang Janni","startDate":"2012-02","conditions":"HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells","enrollment":105},{"nctId":"NCT01591577","phase":"PHASE2","title":"Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2012-12-07","conditions":"Newly Diagnosed Glioblastoma Multiforme","enrollment":50},{"nctId":"NCT01199367","phase":"PHASE1","title":"Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-12","conditions":"Breast Cancer","enrollment":11},{"nctId":"NCT00424164","phase":"PHASE1","title":"Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2006-11","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT03894410","phase":"","title":"Real World Study of Lapatinib Among Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Fudan University","startDate":"2019-01-10","conditions":"Breast Cancer","enrollment":242},{"nctId":"NCT04001634","phase":"","title":"Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC","status":"COMPLETED","sponsor":"Fudan University","startDate":"2015-01-01","conditions":"Breast Cancer","enrollment":285},{"nctId":"NCT03500380","phase":"PHASE2, PHASE3","title":"A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2018-04-24","conditions":"Breast Neoplasms, Breast Diseases, Capecitabine","enrollment":301},{"nctId":"NCT01300962","phase":"PHASE1","title":"Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2011-08","conditions":"Metastatic Breast Cancer","enrollment":47},{"nctId":"NCT03262935","phase":"PHASE3","title":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Byondis B.V.","startDate":"2017-12-15","conditions":"Metastatic Breast Cancer","enrollment":437},{"nctId":"NCT01711658","phase":"PHASE2","title":"TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2013-03-15","conditions":"Non-HPV Locally Advanced Head and Neck Cancer","enrollment":142},{"nctId":"NCT01622868","phase":"PHASE2","title":"Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-12-06","conditions":"HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain","enrollment":143},{"nctId":"NCT01873833","phase":"PHASE2","title":"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2013-07-29","conditions":"HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer","enrollment":10},{"nctId":"NCT04591431","phase":"PHASE2","title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","status":"UNKNOWN","sponsor":"Fondazione per la Medicina Personalizzata","startDate":"2020-10-07","conditions":"Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT00455039","phase":"PHASE1, PHASE2","title":"INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2023-07-31","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01138384","phase":"PHASE1, PHASE2","title":"Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2010-10-27","conditions":"Breast Cancer","enrollment":19},{"nctId":"NCT03084939","phase":"PHASE3","title":"Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-04-24","conditions":"Breast Cancer","enrollment":351},{"nctId":"NCT00272987","phase":"PHASE3","title":"ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12-13","conditions":"Neoplasms, Breast","enrollment":63},{"nctId":"NCT00841828","phase":"PHASE2","title":"Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2009-02","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT00251433","phase":"PHASE1","title":"GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09-26","conditions":"Neoplasms, Breast","enrollment":53},{"nctId":"NCT00281658","phase":"PHASE3","title":"Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-01-02","conditions":"Neoplasms, Breast","enrollment":444},{"nctId":"NCT00807859","phase":"PHASE1","title":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-03-09","conditions":"Breast Cancer, Breast Neoplasms, Breast Tumors","enrollment":65},{"nctId":"NCT00436566","phase":"PHASE2","title":"Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-03-16","conditions":"Breast Cancer, Cardiac Toxicity","enrollment":122},{"nctId":"NCT05467189","phase":"","title":"Antineoplastic Drugs in Elderly Patients","status":"RECRUITING","sponsor":"Shandong University","startDate":"2021-01-01","conditions":"Cancer","enrollment":500},{"nctId":"NCT04850625","phase":"","title":"Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-01-15","conditions":"Breast Cancer","enrollment":224},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT00447122","phase":"PHASE1","title":"BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer","status":"TERMINATED","sponsor":"Brown University","startDate":"2007-03","conditions":"Metastatic Pancreatic Cancer","enrollment":25},{"nctId":"NCT01499160","phase":"PHASE2","title":"Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2012-05","conditions":"Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis","enrollment":7},{"nctId":"NCT00952692","phase":"PHASE1, PHASE2","title":"Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Michael Morse, MD","startDate":"2009-07","conditions":"Metastatic Breast Cancer","enrollment":12},{"nctId":"NCT00444535","phase":"PHASE2","title":"Lapatinib and Bevacizumab for Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-02-27","conditions":"Neoplasms, Breast","enrollment":52},{"nctId":"NCT02213042","phase":"PHASE2","title":"Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-10-24","conditions":"Neoplasms, Breast","enrollment":42},{"nctId":"NCT00206427","phase":"PHASE2","title":"Neoadjuvant GW572016 to Treat Breast Cancer","status":"COMPLETED","sponsor":"Baylor Breast Care Center","startDate":"2004-08","conditions":"Breast Cancer","enrollment":49},{"nctId":"NCT02073487","phase":"PHASE2","title":"Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2014-02","conditions":"Breast Cancer","enrollment":32},{"nctId":"NCT00508274","phase":"PHASE3","title":"Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07-18","conditions":"Neoplasms, Breast","enrollment":52},{"nctId":"NCT00553358","phase":"PHASE3","title":"Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-01-05","conditions":"Neoplasms, Breast","enrollment":455},{"nctId":"NCT01808573","phase":"PHASE3","title":"A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2013-03-29","conditions":"HER2+ Metastatic Breast Cancer (MBC)","enrollment":621},{"nctId":"NCT04899128","phase":"","title":"Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-08-01","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT01636908","phase":"NA","title":"Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2011-08","conditions":"Cancer, Advanced Solid Tumors","enrollment":43},{"nctId":"NCT04831528","phase":"","title":"Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2021-04-10","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT00073528","phase":"PHASE3","title":"Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-12-09","conditions":"Breast Neoplasms","enrollment":1286},{"nctId":"NCT02650752","phase":"PHASE1","title":"Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-01-06","conditions":"Metastatic Breast Cancer, Central Nervous System (CNS) Metastases","enrollment":11},{"nctId":"NCT00863122","phase":"EARLY_PHASE1","title":"Concentration and Activity of Lapatinib in Vestibular Schwannomas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2009-06","conditions":"Vestibular Schwannoma, NF2, Neurofibromatosis 2","enrollment":26},{"nctId":"NCT01471847","phase":"PHASE1","title":"A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-02","conditions":"Locally Advance Breast Cancer (LABC), Metastatic Breast Cancer (MBC)","enrollment":5},{"nctId":"NCT01190241","phase":"NA","title":"Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2010-08","conditions":"Advanced Solid Tumors, Inoperable, Metastasis","enrollment":45},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00367471","phase":"PHASE1","title":"Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12-07","conditions":"Neoplasms, Breast","enrollment":31},{"nctId":"NCT01875666","phase":"EARLY_PHASE1","title":"Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2013-08-05","conditions":"Breast Neoplasms","enrollment":26},{"nctId":"NCT00883688","phase":"PHASE2","title":"Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-07","conditions":"Brain Cancer, Pediatric Cancers","enrollment":24},{"nctId":"NCT00085020","phase":"PHASE1","title":"GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2004-03","conditions":"Breast Cancer","enrollment":13},{"nctId":"NCT02362958","phase":"PHASE2","title":"A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-01-09","conditions":"HER2 Positive Breast Cancer","enrollment":159},{"nctId":"NCT00543504","phase":"PHASE1","title":"Bevacizumab in Multiple Phase I Combinations","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-10-10","conditions":"Advanced Cancer","enrollment":343},{"nctId":"NCT03080805","phase":"PHASE3","title":"Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-05-03","conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT00684983","phase":"PHASE2","title":"Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-30","conditions":"HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7","enrollment":64},{"nctId":"NCT01044433","phase":"PHASE2","title":"Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2009-10","conditions":"Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary","enrollment":44},{"nctId":"NCT00331630","phase":"EARLY_PHASE1","title":"Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2006-05-04","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT00439179","phase":"PHASE1","title":"A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema","status":"COMPLETED","sponsor":"Brown University","startDate":"2006-07","conditions":"Metastatic Pancreatic Cancer","enrollment":27},{"nctId":"NCT00939523","phase":"PHASE2","title":"Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2009-07","conditions":"Pituitary Adenomas, Prolactinomas","enrollment":9},{"nctId":"NCT00390455","phase":"PHASE3","title":"Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-09-15","conditions":"Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative","enrollment":295},{"nctId":"NCT01827163","phase":"PHASE2","title":"Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-04","conditions":"HER2-Positive Early Stage Breast Cancer","enrollment":20},{"nctId":"NCT00574171","phase":"PHASE2","title":"Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2007-09","conditions":"Metastatic Colorectal Cancer","enrollment":29},{"nctId":"NCT00263588","phase":"PHASE2","title":"Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12-02","conditions":"Neoplasms, Breast","enrollment":242},{"nctId":"NCT04185649","phase":"PHASE3","title":"The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Bio-Thera Solutions","startDate":"2018-07-01","conditions":"HER2-positive Advanced Breast Cancer","enrollment":410},{"nctId":"NCT01118975","phase":"PHASE1, PHASE2","title":"GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2010-03","conditions":"Breast Cancer, Neoplasm Metastasis","enrollment":12},{"nctId":"NCT01264081","phase":"PHASE2","title":"Lapatinib in Stage IV Melanoma With ERBB4 Mutations","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-20","conditions":"Malignant Melanoma","enrollment":34},{"nctId":"NCT01783756","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2013-06-26","conditions":"Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer","enrollment":9},{"nctId":"NCT00548184","phase":"PHASE2","title":"Lapatinib and Trastuzumab With or Without Endocrine Therapy","status":"COMPLETED","sponsor":"Baylor Breast Care Center","startDate":"2008-05","conditions":"Breast Cancer","enrollment":65},{"nctId":"NCT00820872","phase":"PHASE2","title":"Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-02","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT01891357","phase":"PHASE2","title":"Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer","status":"TERMINATED","sponsor":"West German Study Group","startDate":"2013-09-30","conditions":"Carcinoma, Ductal, Breast","enrollment":64},{"nctId":"NCT02056080","phase":"","title":"Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib","status":"COMPLETED","sponsor":"MedSIR","startDate":"2013-01","conditions":"Breast Neoplasm","enrollment":111},{"nctId":"NCT00113373","phase":"PHASE2","title":"Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-05","conditions":"Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer","enrollment":28},{"nctId":"NCT00096447","phase":"PHASE2","title":"Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11","conditions":"Recurrent Endometrial Carcinoma","enrollment":31},{"nctId":"NCT02294786","phase":"PHASE2","title":"Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12-17","conditions":"Cancer","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":51,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tykerb"],"phase":"phase_3","status":"active","brandName":"lapatinib (GW572016)","genericName":"lapatinib (GW572016)","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lapatinib is a small-molecule tyrosine kinase inhibitor that blocks HER2 and EGFR signaling to inhibit cancer cell growth. Used for HER2-positive metastatic breast cancer (in combination with capecitabine), HER2-positive early-stage breast cancer (adjuvant therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}